Roquefort Investments PLC ( (GB:ROQ) ) has issued an announcement.
Roquefort Therapeutics PLC has successfully raised £236,000 through a private placing of new ordinary shares, priced at a 6.25% discount to the previous closing price. Additionally, the company has converted £50,000 of convertible loan notes into new shares. The funds will support general working capital as Roquefort progresses towards completing significant transactions with Lyramid Pty Ltd and Oncogeni Ltd, aiming to leverage these deals for further growth opportunities. The company remains focused on maintaining a reduced cost base and ensuring sufficient financial capacity to execute its strategic objectives over the next year.
More about Roquefort Investments PLC
Roquefort Therapeutics PLC is a biotech company listed on the Main Market, focusing on developing first-in-class drugs in the high-value and high-growth immunology and oncology sectors. The company’s portfolio includes five novel, patent-protected pre-clinical anti-cancer and immunology assets.
YTD Price Performance: -60.49%
Average Trading Volume: 2,406,287
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £2.48M
See more data about ROQ stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com